Association of apolipoprotein E gene polymorphism with end-stage renal disease and hyperlipidemia in patients on long-term hemodialysis

References

• Van Tits L, De Graf J, Hak-Lemmers H, et al. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab Invest. 2003;83:13–21
   PubMed Web of Science ®Google Scholar
• Atman PO, Samuelsson OG, Moberly J, et al. Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis. Kidney Int. 1999;55:1536–1542
   Google Scholar
• Schiavon R, Battaglia P, De Fanti E, et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients. comparison with the PON1 allele polymorphism. Clin Chim Acta. 2002;324:39–44
   PubMed Web of Science ®Google Scholar
• Cedazo-Mínguez A. Apolipoprotein E and Alzheimer’s disease: Molecular mechanisms and therapeutic opportunities. J Cell Mol Med. 2007;11:1227–1238
   PubMed Web of Science ®Google Scholar
• Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–630
   PubMed Web of Science ®Google Scholar
• Lahrach H, Ghalim N, Taki H, et al. Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term. J Clin Lipid. 2008;2:43–50
   PubMed Web of Science ®Google Scholar
• Friedwald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
   PubMed Web of Science ®Google Scholar
• Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart JC. Differential electro-immunoassay of human LpAI lipoprotein particles on ready to-use-plates. Clin Chem. 1990;36:1431–1435
   PubMed Web of Science ®Google Scholar
• Paragh G, Asztalos L, Seres I, et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron. 1999;83:126–131
   PubMed Web of Science ®Google Scholar
• Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545–548
   PubMed Web of Science ®Google Scholar
• Tascilar N, Dursun A, Ankarali H, et al. Relationship of apoE polymorphism with lipoprotein(a), apoA, apoB and lipid levels in atherosclerotic infarct. J Neurol Sci. 2009;277:17–21
   Google Scholar
• Oda H, Yorioka N, Ueda C, Kushihata S, Yamakido M. Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl. 1999;71:25–27
   Google Scholar
• Liberopoulos EN, Miltiadous GA, Cariolou M, Tselepis AD, Siamopoulos KC, Elisaf MS. The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in patients. Am J Kidney Dis. 2004;44:300–308
   PubMed Web of Science ®Google Scholar
• Hubacek JA, Bloudickova S, Kubinova R, Pikhart H, Viklicky O, Bobak M; and for the MIA group. Apolipoprotein E polymorphism in hemodialysed patients and healthy controls. Biochem Genet. 2009;47:688–693
   Google Scholar
• Güz G, Nurhan Ozdemir F, Sezer S, et al. Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in patients. Am J Kidney Dis. 2000;36:826–836
   PubMed Web of Science ®Google Scholar
• Feussner G, Wey S, Bommer J, Deppermann D, Grutzmacher P, Ziegler R. Apolipoprotein E phenotypes and hyperlipidemia in patients under maintenance of hemodialysis. Hum Genet. 1992;88:307–312
   PubMed Web of Science ®Google Scholar
• Eggertsen G, Heimburger O, Stenvinkel P, Berglund L. Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. Nephrol Dial Transplant. 1997;12:141–144
   PubMed Web of Science ®Google Scholar
• Imura T, Kimura H, Gejyo F. Apolipoprotein E phenotypes in patients on hemodialysis. Kidney Int Suppl. 1999;71:245–247
   Google Scholar
• Cofán F, Cofan M, Rosich E, et al. Effect of apolipoprotein E polymorphism on renal transplantation. Transplant Proc. 2007;39:2217–2218
   Google Scholar
• Lerique B, Moulin B, Delpero C, Purgus R, Olmer M, Boyer J. Apolipoprotein E phenotype and hyperlipoproteinemia in nephrotic syndrome. Clin Chem. 1994;40:849–850
   Google Scholar
• Roussos L, Floren CH, Carlson J, Svensson PJ, Wallmark A, Ekberg H. Increased prevalence of apolipoprotein E3/E4 genotype among Swedish renal transplant recipients. Nephron. 1990;83:25–30
   Google Scholar
• Chu AY, Parekh RS, Astor BC, et al. Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: A Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study. BMC Med Genet. 2009;10:108
   PubMed Web of Science ®Google Scholar
• Roussos L, Ekström U, Ehle PN, Oqvist B, Floren CH. Apolipoprotein E polymorphism in 385 patients on renal replacement therapy in Sweden. Scand J Urol Nephrol. 2004;38(6):504–510
   PubMed Web of Science ®Google Scholar
• Valveny N, Esteban E, Kandil M, Moral P. Apo E polymorphism in Spanish and Moroccan populations. Clin Genet. 1997;51:354–356
   PubMed Web of Science ®Google Scholar
• Kacemi LN, Bamou Y, Guedira A, et al. Polymorphisme de l'apolipoprotéine E dans une population marocaine: Fréquence allélique et relation avec les paramètres lipidiques plasmatiques. Ann Biol Clin. 2002;60:73–78
   Google Scholar
• Bennouar N, Allami A, Laraqui A, et al. Implication du polymorphisme génétique de l’apolipoprotéine E et de l’enzyme de conversion de l’angiotensine dans l’athérosclérose coronarienne. Ann Biol Clin. 2004;62:295–304
   Google Scholar
• Al-Muhanna F, El-Mueilo S, Al-Ali A, et al. Polymorphism in methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, and apolipoprotein E in patients. Saudi J Kidney Dis Transplant. 2008;19:937–941
   Google Scholar
• Al-Yahyaee SA, Al-Kindi MN, Al-Bahrani AH. Distribution of apolipoprotein E alleles in the Omani population. Med Princ Pract. 2005;14:73–78
   Google Scholar
• Al-Shammari S, Fatania H, Al-Radwan R, Akanji AO. Apolipoprotein E polymorphism and lipoprotein levels in a Gulf Arab population in Kuwait: A pilot study. Ann Saudi Med. 2004;24:361–364
   Google Scholar
• Zahálková J, Vaverková H, Novotný D, Kosatíková Z. Impaired triglyceride tolerance in patients with different apolipoprotein E (Apo E) isoforms. Biomed Papers. 2002;146:73–76
   PubMedGoogle Scholar
• Oda H, Yorioka N, Ueda C, Kushihata S, Yamakido M. Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl. 1999;71:25–27
   Google Scholar
• Arikan H, Koc M, Sari H, Tuglular S, Ozener C, Akoglu E. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients. Ren Fail. 2007;29(6):713–719
   PubMed Web of Science ®Google Scholar
• Akanji AO, Suresh CG, Fatania HR, Al-Radwan R, Zubaid M. Associations of apolipoprotein E polymorphism with low-density lipoprotein size and subfraction profiles in Arab patients with coronary heart disease. Metabolism. 2007;56:484–490
   Google Scholar
• Granér M, Kahri J, Varpula M, et al. Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis. 2008;18:271–277
   PubMed Web of Science ®Google Scholar
• Ravaglia G, Forti P, Maioli F, et al. Apolipoprotein E e4 allele affects risk of hyperhomocysteinemia in the elderly. Am J Clin Nutr. 2006;84:1473–1480
   Google Scholar